Biogen Q4 Non-GAAP Earnings, Revenue Fall; 2026 Outlook Set -- Shares Up Pre-Bell
MT Newswires Live
Feb 06
Biogen (BIIB) reported Q4 non-GAAP earnings Friday of $1.99 per diluted share, down from $3.44 a year earlier.
Analysts polled by FactSet expected $1.63.
Revenue for the quarter ended Dec. 31 was $2.28 billion, down from $2.46 billion a year earlier.
Analysts surveyed by FactSet expected $2.20 billion.
For 2026, the company expects non-GAAP EPS of $15.25 to $16.25 and revenue decline by a mid-single digit percentage from a year earlier.
Analysts polled by FactSet expect non-GAAP EPS of $14.93.
Biogen shares were up 1.3% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.